Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Comparing two techniques for treating coagulation disorders caused by plasmapheresis

Official title: Description of Coagulation Disorders Secondary to Two Plasmapheresis Techniques (Double Filtration Plasmapheresis vs. PFS). Descriptive Pilot Study.

Run by Centre Hospitalier Universitaire de Nīmes · NCT06571552 · Data updated 2026-11-12

This study is testing two different plasmapheresis techniques to see how they affect blood clotting in adults who need ongoing treatment for coagulation disorders.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment6 (estimated)
SponsorCentre Hospitalier Universitaire de Nīmes
Academic / other
Locations1 site (Nîmes, France)
StatusRecruiting
StartedDecember 17, 2024
Main results expectedDecember 17, 2026
Study endsFebruary 2, 2027
Registry record updatedOctober 20, 2026
Trial IDNCT06571552 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults over 18 years old undergoing chronic therapeutic plasmapheresis without renal failure.

Probably not a fit

Patients on anticoagulants, those with certain hematological conditions, or those requiring fresh frozen plasma substitution may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study investigates the effects of two different plasmapheresis techniques—Single Plasma Exchange (SPE) and Double Filtration Plasmapheresis (DFPP)—on coagulation disorders. It aims to document the changes in hemostatic factors and their kinetics following these treatments, as current data is limited and often focuses only on pre- and post-treatment coagulation factor assays. The study will include patients over 18 years old who are undergoing chronic therapeutic plasmapheresis without renal failure. By understanding the impact of these techniques on hemostasis, the study seeks to clarify when and how to correct coagulation deficiencies that may arise post-treatment.

Why it matters

Potential benefit: If successful, this study could improve the management of coagulation disorders in patients undergoing plasmapheresis, potentially reducing the risk of bleeding complications.

How similar studies have gone: While some studies have explored coagulation changes with plasmapheresis, this specific comparison of SPE and DFPP is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients without renal failure treated with chronic therapeutic plasmapheresis with a minimum treatment interval of 10 days and who can be treated with single plasma exchange (SPE) or double filtration plasmapheresis (DFPP) in accordance with the international recommendations.
* Therapeutic plasmapheresis with regional citrate anticoagulation.
* Patients over 18 years of age.
* Patient affiliated to or benefiting from a social security scheme.
* Free, informed and written consent, signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research).

Exclusion Criteria:

* Patients treated with oral anticoagulants or anti-platelet agents.
* Patients treated for hypercholesterolaemia or hypertriglyceridaemia; hyperviscosity, acquired haemophilia or nephrotic syndrome.
* Indication for substitution with fresh frozen plasma (FFP) for the treatment of the disease.
* Patient in an exclusion period determined by another study.
* Patient under court protection, guardianship or curatorship.
* Patient unable to give consent.
* Patient for whom it is impossible to give informed information.
* Pregnant or breast-feeding patients.

Where it's running

  • CHU de Nîmes
    Nîmes, France, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.